Switching from Wegovy injection to pill can be an option a prescriber plans with a patient. Today's OCTANE results offer an early look: a selected group lost an average of 4.1% of body weight over three months after switching.
The group had used either semaglutide injections, the medicine in Wegovy, or tirzepatide injections, the medicine in Zepbound. Everyone included had stayed on the pill for three months. The findings give a reason to discuss a switch, but they don't show that switching beats staying on injections.
Switching from Wegovy injection to pill: today's data
As of September 30, 2026, the day this article was written, Novo reported OCTANE's three-month results at the European Association for the Study of Diabetes meeting in Milan. Researchers looked back at records from Ro, a telehealth platform. Novo funded the study.
The congress poster describes 194 adults, half previously prescribed semaglutide injections and half tirzepatide injections. They had obesity, or overweight with a related health condition. People with a history of diabetes, weight-loss surgery or an eating disorder were excluded.
| What OCTANE measured | Result after three months |
|---|---|
| Average starting weight around the switch | 221.6 pounds |
| Average weight change | 4.1% lower, or 8.8 pounds lost |
| People losing at least 5% | About two in five: 40.7% |
| People in the obesity category | 87.1% at the start, 65.5% afterward |
The obesity category used BMI, a measure of weight relative to height, at 30 or higher. Crossing that cutoff describes a change in weight category. It doesn't mean every related health problem disappeared.
The starting point matters. These figures begin around the pill's start, rather than before the first injection. Earlier weight loss wasn't required for inclusion. The report doesn't give the group's weight change before switching.
What the switch means in practice
The practical change is a daily morning routine in place of a weekly injection. The current U.S. Wegovy label on DailyMed carries the line "Revised: 6/2026".
Its specific switching pathway covers adults using Wegovy 2.4 mg injections for weight reduction or cardiovascular risk reduction. Cardiovascular means involving the heart and blood vessels. The label describes changing to 25 mg tablets daily, beginning one week after stopping that injection.
That pathway isn't a conversion for every injection strength or another medication. The label's usual tablet-starting schedule begins at 1.5 mg daily, then moves through 4 mg and 9 mg to 25 mg. Each starting step lasts 30 days. The prescriber sets the actual transition, timing and dose.
The tablet instructions specify an empty stomach in the morning, up to 4 ounces of plain water, and swallowing the tablet whole. They also require at least 30 minutes before food, other drinks or other oral medicines.
Those details affect how much medicine reaches the blood. In Bækdal and colleagues' two dosing studies, Diabetes Therapy, 2021, eating before the tablet left limited or no measurable medicine in the blood. Longer waits before eating increased the amount absorbed. Our oral semaglutide guide explains the tablet's delivery system.
What these results do not prove
OCTANE had no group that continued injections for comparison. It cannot show how much those same people would have lost if they had stayed on their previous treatment. A change after switching isn't proof that the switch caused it.
The study also required people to remain on the pill, without a supply gap longer than 30 days. People who failed that requirement or lacked follow-up weights weren't included. That's selection bias: who gets counted can make the outcome look different from everyone's experience.
Weights were self-reported, and records collected during ordinary care weren't always complete or timed alike. Three months is also too short to answer whether the weight change lasts. Novo acknowledges these limits in its release.
The earlier OASIS 4 trial, Wharton and colleagues, New England Journal of Medicine, 2025, randomly assigned 307 adults to the 25 mg tablet or placebo, a pill without active medicine. It tested weight management, rather than whether injection users should switch. Digestive side effects occurred in about three in four tablet participants, 74.0%, versus 42.2% with placebo. A pill doesn't remove that part of the treatment conversation.
A switch from Zepbound asks a different question
Moving from Zepbound to Wegovy changes the medicine as well as the route. Both act on GLP-1, a gut-hormone signal involved in fullness and blood sugar. Tirzepatide also acts on GIP, another gut-hormone signal.
OCTANE's headline combines both groups. The 4.1% figure isn't a separate estimate for people leaving Zepbound, or for those leaving Wegovy. The study doesn't establish a tirzepatide-to-tablet dose conversion. A prescriber has to weigh the prior response, side effects, treatment gaps and other medicines.
The broader GLP-1 pills versus injections comparison covers the route choices. Orforglipron is another oral medicine; it wasn't the pill studied in OCTANE.
How the study relates to Promise's formats
Promise's current product pages list plain compounded semaglutide and tirzepatide as injections only. Compounded means a pharmacy prepares the medicine for a particular prescription. These are different preparations from the swallowed Wegovy tablet. OCTANE's results cannot establish the same outcomes for those compounded injections.
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved. FDA explains that compounded drugs do not undergo its review for safety, effectiveness or quality before marketing. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor.
What to watch next
The useful next numbers are how many people remain on the tablet at six or twelve months, including those who struggle or stop. A comparison with people continuing injections would help answer whether switching changes the outcome.
Ro and Novo's September 30 collaboration announcement says more findings are planned for ObesityWeek, November 14–17, 2026. That is a planned presentation, not longer follow-up already in hand. For now, OCTANE describes one selected group's first three months.
At Promise, a licensed provider reviews every request and prescribes only when medically appropriate; not everyone qualifies.
